Chemoprevention of metachronous adenomatous colorectal polyps

• US 5,843,929 A
• Filed: 03/22/1996
• Issued: 12/01/1998
• Est. Priority Date: 03/22/1996
• Status: Expired due to Fees

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Ahlquist, David A., Pearson, Randall K., Larson, Mark V.
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US08/621,781
• Time in Patent Office: 984 Days
• Field of Search: 514/182
• US Class Current: 514/182
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/575 substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• CPC Class Codes: A61K 31/60 Salicylic acid; Derivatives thereof

Abstract

A method for protecting a colorectum against a recurrence of adenomomas is provided, wherein ursodeoxycholic acid, or ursodeoxycholic acid in combination with sulindac, is administered to a patient afflicted with colorectal adenomas in an amount effective to prevent the recurrence of colorectal adenomas following the removal thereof.

Claims

1. A method for protecting a colorectum against a recurrence of colorectal adenomas comprising administering to a human afflicted with colorectal adenomas, an amount of ursodeoxycholic acid or a pharmaceutically acceptable salt thereof, effective to prevent the recurrence of colorectal adenomas following the removal thereof.

2. The method of claim 1 wherein the effective amount of ursodeoxycholic acid or pharmaceutically acceptable salt thereof is administered orally.

3. The method of claim 2 wherein ursodeoxycholic acid is administered at a dose of about 50 to 7500 mg per day.